Genezen and Optieum Partner to Support cGMP Manufacturing of CAR-T Therapy for Glioblastoma
Collaboration supports manufacture of the OPTF01 product to Drive Next-Generation Chimeric Antigen Receptor T Cell (CAR-T) Development Genezen, a leading viral vector Contract Development and Manufacturing Organization and Optieum Biotechnologies,...